440 related articles for article (PubMed ID: 10200159)
1. Peptidomimetic probes and molecular modeling suggest that Alzheimer's gamma-secretase is an intramembrane-cleaving aspartyl protease.
Wolfe MS; Xia W; Moore CL; Leatherwood DD; Ostaszewski B; Rahmati T; Donkor IO; Selkoe DJ
Biochemistry; 1999 Apr; 38(15):4720-7. PubMed ID: 10200159
[TBL] [Abstract][Full Text] [Related]
2. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity.
Yan R; Bienkowski MJ; Shuck ME; Miao H; Tory MC; Pauley AM; Brashier JR; Stratman NC; Mathews WR; Buhl AE; Carter DB; Tomasselli AG; Parodi LA; Heinrikson RL; Gurney ME
Nature; 1999 Dec; 402(6761):533-7. PubMed ID: 10591213
[TBL] [Abstract][Full Text] [Related]
3. Are presenilins intramembrane-cleaving proteases? Implications for the molecular mechanism of Alzheimer's disease.
Wolfe MS; De Los Angeles J; Miller DD; Xia W; Selkoe DJ
Biochemistry; 1999 Aug; 38(35):11223-30. PubMed ID: 10471271
[TBL] [Abstract][Full Text] [Related]
4. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity.
Wolfe MS; Xia W; Ostaszewski BL; Diehl TS; Kimberly WT; Selkoe DJ
Nature; 1999 Apr; 398(6727):513-7. PubMed ID: 10206644
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel aspartic protease (Asp 2) as beta-secretase.
Hussain I; Powell D; Howlett DR; Tew DG; Meek TD; Chapman C; Gloger IS; Murphy KE; Southan CD; Ryan DM; Smith TS; Simmons DL; Walsh FS; Dingwall C; Christie G
Mol Cell Neurosci; 1999 Dec; 14(6):419-27. PubMed ID: 10656250
[TBL] [Abstract][Full Text] [Related]
6. Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease.
Pollack SJ; Lewis H
Curr Opin Investig Drugs; 2005 Jan; 6(1):35-47. PubMed ID: 15675602
[TBL] [Abstract][Full Text] [Related]
7. Targeting BACE with small inhibitory nucleic acids - a future for Alzheimer's disease therapy?
Nawrot B
Acta Biochim Pol; 2004; 51(2):431-44. PubMed ID: 15218540
[TBL] [Abstract][Full Text] [Related]
8. The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer's disease brain.
Stockley JH; O'Neill C
Biochem Soc Trans; 2007 Jun; 35(Pt 3):574-6. PubMed ID: 17511655
[TBL] [Abstract][Full Text] [Related]
9. BACE2, a beta -secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein.
Farzan M; Schnitzler CE; Vasilieva N; Leung D; Choe H
Proc Natl Acad Sci U S A; 2000 Aug; 97(17):9712-7. PubMed ID: 10931940
[TBL] [Abstract][Full Text] [Related]
10. A substrate-based difluoro ketone selectively inhibits Alzheimer's gamma-secretase activity.
Wolfe MS; Citron M; Diehl TS; Xia W; Donkor IO; Selkoe DJ
J Med Chem; 1998 Jan; 41(1):6-9. PubMed ID: 9438016
[No Abstract] [Full Text] [Related]
11. Familial Alzheimer's disease mutations inhibit gamma-secretase-mediated liberation of beta-amyloid precursor protein carboxy-terminal fragment.
Wiley JC; Hudson M; Kanning KC; Schecterson LC; Bothwell M
J Neurochem; 2005 Sep; 94(5):1189-201. PubMed ID: 15992373
[TBL] [Abstract][Full Text] [Related]
12. A presenilin-independent aspartyl protease prefers the gamma-42 site cleavage.
Lai MT; Crouthamel MC; DiMuzio J; Pietrak BL; Donoviel DB; Bernstein A; Gardell SJ; Li YM; Hazuda D
J Neurochem; 2006 Jan; 96(1):118-25. PubMed ID: 16300640
[TBL] [Abstract][Full Text] [Related]
13. Aspartic proteases involved in Alzheimer's disease.
Schmidt B
Chembiochem; 2003 May; 4(5):366-78. PubMed ID: 12740808
[TBL] [Abstract][Full Text] [Related]
14. Modeling of substrate specificity of the Alzheimer's disease amyloid precursor protein beta-secretase.
Sauder JM; Arthur JW; Dunbrack RL
J Mol Biol; 2000 Jul; 300(2):241-8. PubMed ID: 10873463
[TBL] [Abstract][Full Text] [Related]
15. beta-Secretase, APP and Abeta in Alzheimer's disease.
Vassar R
Subcell Biochem; 2005; 38():79-103. PubMed ID: 15709474
[TBL] [Abstract][Full Text] [Related]
16. Catalytic site-directed gamma-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and beta-APP cleavages.
Lewis HD; Pérez Revuelta BI; Nadin A; Neduvelil JG; Harrison T; Pollack SJ; Shearman MS
Biochemistry; 2003 Jun; 42(24):7580-6. PubMed ID: 12809514
[TBL] [Abstract][Full Text] [Related]
17. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets.
Evin G; Zhu A; Holsinger RM; Masters CL; Li QX
J Neurosci Res; 2003 Nov; 74(3):386-92. PubMed ID: 14598315
[TBL] [Abstract][Full Text] [Related]
18. FAD mutations in presenilin-1 or amyloid precursor protein decrease the efficacy of a gamma-secretase inhibitor: evidence for direct involvement of PS1 in the gamma-secretase cleavage complex.
Xia W; Ostaszewski BL; Kimberly WT; Rahmati T; Moore CL; Wolfe MS; Selkoe DJ
Neurobiol Dis; 2000 Dec; 7(6 Pt B):673-81. PubMed ID: 11114265
[TBL] [Abstract][Full Text] [Related]
19. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1.
Li YM; Xu M; Lai MT; Huang Q; Castro JL; DiMuzio-Mower J; Harrison T; Lellis C; Nadin A; Neduvelil JG; Register RB; Sardana MK; Shearman MS; Smith AL; Shi XP; Yin KC; Shafer JA; Gardell SJ
Nature; 2000 Jun; 405(6787):689-94. PubMed ID: 10864326
[TBL] [Abstract][Full Text] [Related]
20. Difluoro ketone peptidomimetics suggest a large S1 pocket for Alzheimer's gamma-secretase: implications for inhibitor design.
Moore CL; Leatherwood DD; Diehl TS; Selkoe DJ; Wolfe MS
J Med Chem; 2000 Sep; 43(18):3434-42. PubMed ID: 10978191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
